PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TYPE 2 TREATMENT MARKET ANALYSIS

Market News

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market: Key Developments

On June 12, 2023, Ipsen, a global, mid-sized biopharmaceutical company, announced that the company will present data from across its growing rare liver disease portfolio at the European Association for the Trial of Liver (EASL) Congress 2023 in Vienna, Austria. These include seven abstracts on new clinical data being presented on Bylvay (odevixibat) when used in patients with progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). The Bylvay abstracts give more insight into the efficacy and safety profile of the therapy when applied to subgroups of both paediatric and adult PFIC patients. The data report on outcomes includes event-free survival, reduction in serum bile acids (sBAs), pruritus, and other quality of life outcomes in long-term clinical trials and real-world settings.

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market: Key Trends

• Positive clinical trials result in progressive familial intrahepatic cholestasis type 2: The positive clinical trial results of progressive familial intrahepatic cholestasis type 2 are one major factor in market growth over the forecast period. In addition to the positive clinical trial results, the increasing prevalence of progressive familial intrahepatic cholestasis type 2 worldwide is expected to contribute significantly to market growth. Furthermore, the rising adoption of advanced diagnostic techniques and therapeutic options for managing this condition is anticipated to drive market expansion even further. Moreover, the growing awareness among healthcare professionals and patients about the importance of early diagnosis and treatment of progressive familial intrahepatic cholestasis type 2 is likely to fuel market demand. Additionally, government initiatives aimed at improving healthcare infrastructure and providing better access to healthcare services are expected to support market growth for this condition.

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market: Key Developments

On June 12, 2023, Ipsen, a global, mid-sized biopharmaceutical company, announced that the company will present data from across its growing rare liver disease portfolio at the European Association for the Trial of Liver (EASL) Congress 2023 in Vienna, Austria. These include seven abstracts on new clinical data being presented on Bylvay (odevixibat) when used in patients with progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). The Bylvay abstracts give more insight into the efficacy and safety profile of the therapy when applied to subgroups of both paediatric and adult PFIC patients. The data report on outcomes includes event-free survival, reduction in serum bile acids (sBAs), pruritus, and other quality of life outcomes in long-term clinical trials and real-world settings.